Press Release
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon reported Q4FY26 total income of Rs 4,569 crore, up 10% YoY, with EBITDA at Rs 1,073 crore (23% margin) and net profit before exceptional items at Rs 179 crore, up 64% YoY on adjusted basis. For full year FY26, total income stood at Rs 17,270 crore (up 14% YoY), EBITDA at Rs 3,798 crore (22% margin, up 200 basis points on like-to-like basis), and net profit before exceptional items at Rs 436 crore, up 323% YoY. Biosimilars segment was the key growth driver with 16% YoY revenue growth to Rs 10,431 crore and 40% EBITDA growth. The company completed integration of its biosimilars and generics businesses into a unified biopharma entity. Board recommended a dividend of Rs 0.50 per share and announced new independent director appointments.
Strong operational performance with margin expansion and robust profit growth signals improving profitability trajectory. The exceptional items (Rs 403 crore for FY26) include integration-related charges but underlying business remains healthy with 200 bps margin improvement.